Influence of inflammatory bowel disease on different dimensions of quality of life

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 5, 2001, Pages 567-572

  Casellas, Francesc ^a   López Vivancos, Josefa ^b   Badia, Xavier ^c   Vilaseca, Jaime ^a   Malagelada, Juan Ramon ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

^c Institut Universitari de Salut Publica de Catalunya   (Spain)

Author keywords

Crohn s disease; Health related quality of life; Healthcare; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; CROHN DISEASE; EMOTIONAL STRESS; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REMISSION; SCORING SYSTEM; SOCIAL DISABILITY; SPAIN; SYMPTOM; ULCERATIVE COLITIS; WELLBEING;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0034997699     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200105000-00017     Document Type: Article

References (25)

1. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
2. Mitchell A, Guyatt G, Singer J, Irvine EJ. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 306-310.
3. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R. et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810.
4. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health related quality of life in inflammatory bowel disease: Functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379-1386.
5. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35-42.
6. Russel MG, Nieman FH, Bergers JM, Stockbrügger RW. Cigarette smoking and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8: 1075-1081.
7. Eisen GM, Farmer RG. Health-related quality of life in inflammatory bowel disease. Pharmacoeconomics 1996; 10: 327-335.
8. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; i: 514
9. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989; 298: 82-86.
10. López-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada J-R. Validation of the Spanish version of the inflammatory bowel disease questionnaire in ulcerative colitis and Crohn’s disease. Digestion 1999; 60: 274-280.
11. Badia X, Gutiérrez F, Wiklund I, Alonso J. Validity and reliability of the Spanish version of psychological general well-being index. Qual Life Res 1996; 5: 101-108.
12. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15-19.
13. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27: 5178-5189.
14. Fraga X, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada J-R. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 683-687.
15. Guyatt GH, Veldhuyzen Van Zanten SJO, Fenny DH, Patrick DL. Measuring quality of life in clinical trials: A taxonomy and review. Can Med Assoc J 1982; 140: 1141-1148.
16. Fitzpatrick R, Fletcher A, Gore S. Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992; 305: 1074-1077.
17. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-629.
18. Irvine EJ, Grace E, Kerr GD, Lyrenas E, Bolin T, O’Morain C. et al. Problems which address health related quality of life (HRQOL) in inflammatory bowel disease (IBD). Gastroenterology 1998; 114: A1002.
19. Levenstein S, Li Z, Scottsdale AZ, Drossman D. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Gastroenterology 1998; 114: A1021
20. De Boer A, Wijker W, Bartelsman J, de Haes HCJM. Inflammatory bowel disease questionnaire: Cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol 1995; 7: 1043-1050.
21. Irvine J, Feagan B, Rochon R, Archambault A, Fedorak RN, Groll A. et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-296.
22. Feagan B, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L. et al. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995; 332: 292-297.
23. Martin F, Sutherland L, Beck IT. Oral 5-ASA versus prednisone in active Crohn’s disease: Results of a randomized placebo controlled, double-blind, multicenter trial. Can J Gastroenterol 1990; 4: 452-457.
24. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR. et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 1999; 117: 527-535.
25. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academy Press; 1977.